Effect of daridorexant on nighttime wakefulness and next-morning sleepiness: assessing the transition from night to day in insomnia disorder
Sleep Medicine · 2025
DOI: 10.1016/j.sleep.2025.106523 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Sleep Medicine, 2025. Verfasst von Yves Dauvilliers und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Reference Centre for Orphan Diseases, Narcolepsy-Rare Hypersomnias, Sleep Unit, Department of Neurology, CHU Montpellier, Institute for Neur…. Hauptthemen laut MEDLINE: Wakefulness, Sleep Initiation and Maintenance Disorders, Sleepiness. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Idorsia Pharmaceuticals Ltd.
Themen: Schlaf
Abstract (Originalsprache)
OBJECTIVE/BACKGROUND: Reducing wakefulness throughout the night without next-day residual effects are essential characteristics for drugs for chronic insomnia disorder. In Phase 3 trials, daridorexant significantly reduced polysomnography-determined wake after sleep onset (WASO) versus placebo, and rates of daytime somnolence were similar to placebo. This analysis examines the effect of daridorexant on WASO in each 2-h quarter (Q) of the night (8-h recording), and on next-morning sleepiness, daytime alertness and ability to function (assessed daily using visual analog scales [VAS]), and the correlation between these night and day assessments. PATIENTS/METHODS: Data from 930 patients with insomnia disorder randomized to daridorexant 50 mg (n = 310), 25 mg (n = 310) or placebo (n = 310) for 3 months were analyzed. RESULTS: At Month 1, daridorexant 25 mg and 50 mg significantly decreased WASO versus placebo in Q2 (least-square mean difference [LSMD] 25 mg: -4.7 min p 25 mg > placebo. No significant correlations were found between WASO (overall and at any quarter) and the three VAS scores. CONCLUSION: Daridorexant reduces wakefulness throughout the entire night while independently decreasing morning sleepiness and improving daytime functioning and alertness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Reference Centre for Orphan Diseases, Narcolepsy-Rare Hypersomnias, Sleep Unit, Department of Neurology, CHU Montpellier, Institute for Neurosciences of Montpellier INM, Univ Montpellier, INSERM, Montpellier, F…
- Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123, Allschwil, Switzerland. Electronic address: guy.braunstein@ext.idorsia.com.
- Clinilabs Drug Development Corporation, New York, NY, USA. Electronic address: gzammit@clinilabs.com.
- Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123, Allschwil, Switzerland. Electronic address: antonio.olivieri@idorsia.com.
- Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123, Allschwil, Switzerland. Electronic address: luyetpierre@hotmail.com.
Förderung
- Idorsia Pharmaceuticals Ltd
Zitieren
APA
Dauvilliers, Y., Braunstein, G., Zammit, G., Olivieri, A., & Luyet, P. P. (2025). Effect of daridorexant on nighttime wakefulness and next-morning sleepiness: assessing the transition from night to day in insomnia disorder. Sleep Medicine. https://doi.org/10.1016/j.sleep.2025.106523
Vancouver
Dauvilliers Y, Braunstein G, Zammit G, Olivieri A, Luyet PP. Effect of daridorexant on nighttime wakefulness and next-morning sleepiness: assessing the transition from night to day in insomnia disorder. Sleep Medicine. 2025. doi:10.1016/j.sleep.2025.106523
BibTeX
@article{Dauvilliers2025,
author = {Dauvilliers, Yves and Braunstein, Guy and Zammit, Gary and Olivieri, Antonio and Luyet, Pierre-Philippe},
title = {Effect of daridorexant on nighttime wakefulness and next-morning sleepiness: assessing the transition from night to day in insomnia disorder},
journal = {Sleep Medicine},
year = {2025},
doi = {10.1016/j.sleep.2025.106523}
}
EUVIMED